期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
Adjuvant therapy for orbital non-rhabdomyosarcoma soft tissue sarcoma:comparison of long-term outcome between radiotherapy and chemotherapy
1
作者 Xiao-Feng Li Rui-Qi Ma +3 位作者 Xue Wu Lu Gan Zhi-Yu Peng Jiang Qian 《International Journal of Ophthalmology(English edition)》 SCIE CAS 2023年第3期402-410,共9页
AIM:To illustrate clinicopathological features of orbital non-rhabdomyosarcoma soft tissue sarcoma(NRSTS),and to compare the treatment outcome between postoperative radiotherapy(RT) and chemotherapy in a retrospective... AIM:To illustrate clinicopathological features of orbital non-rhabdomyosarcoma soft tissue sarcoma(NRSTS),and to compare the treatment outcome between postoperative radiotherapy(RT) and chemotherapy in a retrospective analysis nearly 20y.METHODS:A retrospective cohort study of 56 patients with orbital NRSTS were reviewed,34 of whom received postoperative RT,and 22 received postoperative chemotherapy.The clinicopathological features,local recurrence,metastases,and survival data were recorded.Survival analysis was performed using the Kaplan-Meier method.RESULTS:During follow-up(111.8mo,ranged 8-233mo) for 56 patients,19 patients of them developed local recurrence,and 7 patients developed distant metastases.Fifteen patients died during follow-up period.Overall survival rates considering the whole study group was 78.57% at 5y,and 72.16% at 10y after the initial diagnosis.Compared with chemotherapy,RT was associated with lower risk of local recurrence [hazard ratio for RT vs chemotherapy,0.263,95% confidence interval(CI),0.095-0.728,P=0.0015];with lower risk of distant metastasis(hazard ratio for RT vs chemotherapy,0.073,95%CI,0.015-0.364,P=0.0014);and with lower risk of death from disease(hazard ratio for RT vs chemotherapy,0.066,95%CI,0.022-0.200,P<0.0001).The 5-year survival rate in RT group was 97.06% compared to 50% in chemotherapy group.CONCLUSION:In patients with orbital NRSTS,postoperative RT provides better control of local recurrence,distant metastasis,and death from disease than chemotherapy.RT is the more preferrable adjuvant therapy compared to chemotherapy possibly. 展开更多
关键词 orbital tumor non-rhabdomyosarcoma soft tissue sarcoma oncological outcome adjuvant radiotherapy adjuvant chemotherapy
下载PDF
大剂量异环磷酰胺治疗进展期软组织肉瘤的疗效评价 被引量:3
2
作者 鲁明骞 向丽娥 +5 位作者 徐光川 陈晓勤 文彩虹 许新华 王杰 彭绪申 《肿瘤》 CAS CSCD 北大核心 2007年第1期70-72,共3页
目的:评价大剂量异环磷酰胺治疗进展期软组织肉瘤的临床疗效和不良反应。方法:进展期软组织肉瘤患者24例,异环磷酰胺总量14g/m^2持续灌注24h,第1~6天行常规美斯钠(mesna)解毒和水化,28d为1个周期,共完成1~4个周期,中位周期... 目的:评价大剂量异环磷酰胺治疗进展期软组织肉瘤的临床疗效和不良反应。方法:进展期软组织肉瘤患者24例,异环磷酰胺总量14g/m^2持续灌注24h,第1~6天行常规美斯钠(mesna)解毒和水化,28d为1个周期,共完成1~4个周期,中位周期数为3。结果:全组患者CR3例(12.5%),PR8例(33.3%),SD8例(33.3%),PD5例(20.8%),总有效率45.8%(11/24)。接受一线和二线化疗患者为5例和19例,一线化疗3例获CR或PR;二线化疗8例获CR或PR。主要毒副反应为骨髓抑制,其白细胞Ⅲ~Ⅳ度下降发生率为51.4%,其他不良反应少见。结论:大剂量异环磷酰胺是治疗进展期软组织肉瘤有效化疗方案,患者缓解率较高,毒副反应可以耐受,值得临床进一步观察。 展开更多
关键词 软组织肿瘤 化学疗法 辅助 异环磷酰胺/副作用
下载PDF
^(201)铊显像在骨与软组织良、恶性病变诊断中的应用 被引量:3
3
作者 方向前 范顺武 +1 位作者 楼岑 余林良 《中华骨科杂志》 CAS CSCD 北大核心 2003年第1期41-46,共6页
目的探讨201Tl显像在骨与软组织病变定性诊断中的临床价值。方法对58例骨骼肌肉系统良、恶性病变进行201Tl显像,分别以注射后5min(早期)和2h(延迟期)显像,同时应用肉眼分析和半定量分析。其中6例骨肉瘤病例接受术前新辅助化疗前后均行20... 目的探讨201Tl显像在骨与软组织病变定性诊断中的临床价值。方法对58例骨骼肌肉系统良、恶性病变进行201Tl显像,分别以注射后5min(早期)和2h(延迟期)显像,同时应用肉眼分析和半定量分析。其中6例骨肉瘤病例接受术前新辅助化疗前后均行201Tl定量显像,计算变化率(AR)并与肿瘤坏死率(TNR)进行对照研究。对其中43例骨病变病例与同期进行的99mTc-MDP骨显像结果进行比较。所有病例均经活检和手术后组织学证实,其中恶性骨肿瘤33例,良性骨病变10例,软组织肉瘤10例,软组织良性肿瘤5例。结果半定量分析43例恶性病变和15例良性病变的早期UR分别为2.856±1.121和1.304±0.324,两者的差异有显著性意义(t=5.259,P<0.001);两者的延迟期UR分别为2.261±0.769和1.100±0.139,其差异有显著性意义(t=5.786,P<0.001)。假设早期UR>1.735(2.856-1.121)且延迟期UR>1.492(2.261-0.769)为鉴别良、恶性的阈值,则敏感性为95.35%、特异性为93.33%、精确性为94.83%。6例骨肉瘤病例术前新辅助化疗前后201Tl显像显示变化率与肿瘤坏死率存在良好的相关性,对化疗敏感(TNR>90%)的5例病例化疗后201Tl显像示病灶摄取明显减少。结论201Tl显像的定量研究对骨与软组织病变良、恶性鉴别有重要的临床价值;本研究结果推荐早期UR>1.735,且延迟期UR> 展开更多
关键词 ^201铊 放射性核素显像 骨组织肿瘤 骨肉瘤 化学疗法 诊断 临床应用
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部